changes in weight and metabolic parameters following long-term iloperidone use a meta-analysis of data from 9 phase ii and iii trials of iloperidone体重和代谢参数变化后长期iloperidone使用一个荟萃分析的数据从9 iloperidone的第二和第三阶段试验.pdfVIP

changes in weight and metabolic parameters following long-term iloperidone use a meta-analysis of data from 9 phase ii and iii trials of iloperidone体重和代谢参数变化后长期iloperidone使用一个荟萃分析的数据从9 iloperidone的第二和第三阶段试验.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
changes in weight and metabolic parameters following long-term iloperidone use a meta-analysis of data from 9 phase ii and iii trials of iloperidone体重和代谢参数变化后长期iloperidone使用一个荟萃分析的数据从9 iloperidone的第二和第三阶段试验

Open Journal of Psychiatry, 2012, 2, 414-422 OJPsych /10.4236/ojpsych.2012.224058 Published Online November 2012 (http://www.SciRP.org/journal/ojpsych/) Changes in weight and metabolic parameters following long-term iloperidone use: A meta-analysis of data from 9 Phase II and III trials of iloperidone* Marla Hochfeld, Saeeduddin Ahmed, Xiangyi Meng, Adam Winseck Novartis Pharmaceuticals Corporation, East Hanover, USA Email: marla.hochfeld@ Received 10 September 2012; revised 9 October 2012; accepted 18 October 2012 ABSTRACT can predispose patients with schizophrenia to disease, some antipsychotic medications are associated with Objective: To determine the impact of iloperidone weight gain and changes in glucose and lipids [5-7]. treatment on metabolic parameters. Methods: Data Each antipsychotic drug has a different metabolic profile, were analyzed from 3210 patients who received ilop- in part because of their unique receptor-binding patterns eridone and 587 patients who received placebo for up [8]. Monitoring patients’ metabolic profile during antip- to 2 years during 9 Phase II and Phase III studies sychotic drug use is therefore an important part of patient (integrated safety database). Patients were pooled by

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档